Efficacy and Safety of Vildagliptin and Remogliflozin as add on therapy to Metformin in patients of Type 2 Diabetes Mellitus

Maulana azad medical college0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1.Patients with age between 35 to 70 years of all sexes.
•2.Patients with diagnosis of type 2 diabetes mellitus with uncontrolled glycaemia on taking metformin alone.

•1.Patients on any other anti-diabetic medications other than metformin.
•2. Patients having hepatic dysfunction (aspartate aminotransferase/alanine aminotransferase Ã¢â?°Â¥2.5 times of upper normal limit [UNL] or bilirubin > 2 times of UNL).
•3.Patient with renal dysfunction (with estimated glomerular filtration rate [eGFR] as per MDRD formula < 45 ml/min/1.73 m2.
•4.Patients with genitourinary tract infections.
•5.Patients with lower limb cellulitis, ulcer and amputations.
•6.Patients with osteoporosis and bone fractures.
•7.Patients with acute pancreatitis.
•8.Patients with comorbid serious illness such as tuberculosis, HIV, malignancy.
•9.Patients allergic to the study medications.
•10. Pregnant female patients and nursing mothers will also be excluded.

发起方